Key result
Buflomedil treatment significantly increased erythrocyte filtration flow (p<0.001) and improved haemodynamics in patients with peripheral occlusive arterial disease.
Why the study?
Does buflomedil improve haemodynamic and haemorheological parameters in patients with peripheral occlusive arterial disease?
Does buflomedil improve haemodynamic and haemorheological parameters in patients with peripheral occlusive arterial disease?
Buflomedil administration improves surrogate haemodynamic and haemorheological markers, including red cell deformability, in patients with peripheral occlusive arterial disease.
Answers are grounded in this paper and cite their sources.
May improve haemorheological surrogates in peripheral occlusive arterial disease; leaves open effects on clinical outcomes.
The haemodynamic and haemorheological effects of buflomedil after acute intravenous infusion and after chronic treatment were studied in 25 patients with occlusive arterial diseases of the lower limbs. Acute treatment (100 mg) induced an increase in ankle blood pressure and in peripheral blood velocity, mainly of the continuous flow, as well as a significant decrease in blood viscosity and a significant increase (p less than 0.01) in red cell deformability, expressed as erythrocyte filtration flow. Chronic treatment (200 mg/day for 20 days) showed haemodynamic and haemorheological effects similar to those of the acute infusion, with a highly significant increase (p less than 0.001) in the erythrocyte flow at the end of the treatment period.
No takes yet. Share an insight, caveat, or question.
Perego et al. (1982) studied Peripheral occlusive arterial disease (n=25). Buflomedil was evaluated on Erythrocyte filtration flow (p=<0.001). Buflomedil treatment significantly increased erythrocyte filtration flow (p<0.001) and improved haemodynamics in patients with peripheral occlusive arterial disease.
Synapse has enriched 10 related papers. Consider them for comparative context: